Effect of simvastatin on endothelial function in cardiac syndrome X patients.

Emília Fábián, Albert Varga, Eugenio Picano, Zoltan Vajo, Aladár Rónaszéki, Miklós Csanády

Journal: The American journal of cardiology 2004;94(5):652-5

PMID: 15342302

Full Text on Elsevier Science View on PubMed

Abstract

Patients with cardiac syndrome X with mild hypercholesterolemia were randomized to placebo (n = 20) or simvastatin 20 mg/day (n = 20). In the simvastatin group, there was a significant (26%; p < 0.0001) decrease in total cholesterol, a 38% (p < 0.0001) decrease in low-density lipoprotein cholesterol levels, and 7% a (p < 0.0001) increase in high-density lipoprotein cholesterol levels, without significant changes in triglyceride levels. Brachial artery flow-mediated dilation increased significantly (52% relative increase, p < 0.0001), and the time to > 1-mm ST-segment depression during stress testing was longer by the end of the study (p < 0.0001).

Address: Department of Cardiology, Elizabeth Hospital, Budapest, Hungary. [email protected]

DOI: 10.1016/j.amjcard.2004.05.035

Link outs

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0002...

MeSH Terms: Aged, Anticholesteremic Agents, Endothelium, Vascular, Exercise, Female, Humans, Hypercholesterolemia, Male, Microvascular Angina, Middle Aged, Myocardial Ischemia, Simvastatin, Treatment Outcome